Day: November 9, 2020

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) — EverQuote, Inc. (“EverQuote”), a leading online marketplace for insurance shopping, today announced that management will present and host one-on-one investor meetings at the following investor conferences:RBC Global Technology, Internet, Media, and Telecommunications Virtual ConferenceDate: Tuesday, November 17, 2020Virtual Fireside Chat Time: 10:40 a.m. ETRaymond James Technology Investors ConferenceDate: Monday, December 7, 2020Virtual Fireside Chat Time: 5:00 p.m. ETUBS Technology ConferenceDate: Tuesday, December 8, 2020Virtual Fireside Chat Time: 8:25 a.m. ETConference fireside chats will be available via live audio webcast and archived replay on EverQuote’s investor relations website at http://investors.everquote.com.About EverQuoteEverQuote operates a leading online insurance...

FLORHAM PARK, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that its VERSATILE-002 Phase 2 clinical trial evaluating the combination of PDS0101 and KEYTRUDA® (pembrolizumab) for the first-line treatment of head and neck cancer that has returned or spread is now open. The trial is being conducted in collaboration with Merck.The VERSATILE-002 Phase 2 trial is a multi-center, open label, single arm, non-randomized trial that plans to enroll approximately 100 patients across 25 sites in the U.S. The University of Tennessee Medical Center is the first site to open. The studies to be performed at the...

Reports record Breast Products net sales of $15.3 million, representing 54% sequential growth and 21% year over year growthResults driven by U.S. recovery and market outperformance in the core breast products segmentSANTA BARBARA, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) — Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a diversified medical aesthetics company, today announced its financial results for the third quarter ended September 30, 2020.Jeff Nugent, Sientra’s Chairman and Chief Executive Officer, said, “Sientra recorded exceptional results in Q3, posting 54% sequential quarter over quarter sales growth from Q2’20, despite the strong headwinds our business and the industry have faced from COVID-19.   The third quarter represented significant improvement in net sales in our Breast Products segment. Our pivot to focus...

SCOTTSDALE, Ariz., Nov. 09, 2020 (GLOBE NEWSWIRE) — AgJunction Inc. (TSX: AJX) (“AgJunction” or the “Company”) is reporting financial results for the third quarter ended September 30, 2020. All currency amounts are expressed in U.S. dollars.Third Quarter 2020 Financial Highlights vs. Third Quarter 2019Revenue was $3.8 million versus $8.6 million (Q3 2019 included $5.5 million of revenue related to the Bulk Purchase Order (BPO)).Gross margin increased significantly to 49.7% compared to 32.3%.Operating expenses improved to $2.7 million compared to $5.3 million.Net loss improved to $(0.9) million or $(0.01) per share, versus a net loss of $(2.5) million or $(0.02) per share.EBITDA improved to $(0.2) million versus $(1.9) million.Management Commentary“Throughout the third quarter, we continued to make good progress...

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) — Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today financial results for the three and nine months ended September 30, 2020 and provided an update on key initiatives.Recent EventsAs previously announced on October 29, 2020, Tricida completed an End-of-Review Type A meeting with the FDA on October 20, 2020, that followed a Complete Response Letter (CRL) that was received by the company on August 21, 2020 for the veverimer New Drug Application (NDA) that was under review by the U.S. Food and Drug Administration (FDA) through...

MCLEAN, Va., Nov. 09, 2020 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) recently priced a new offering of Structured Pass-Through Certificates (K Certificates), which are multifamily mortgage-backed securities. The company expects to issue approximately $767 million in K Certificates (K-1518 Certificates), which are expected to settle on or about November 17, 2020.K-1518 PricingDetailsCo-Lead Managers and Joint Bookrunners: PNC Capital Markets LLC and Morgan Stanley & Co. LLCCo-Managers: Brean Capital, LLC, Credit Suisse Securities (USA) LLC, Stern Brothers & Co. and Wells Fargo Securities, LLCRelated LinksThe K-1518 Preliminary Offering Circular Supplement: http://www.freddiemac.com/mbs/data/0k1518oc.pdfFreddie Mac Multifamily Securitization OverviewMultifamily Securities Investor Access database of post-securitization...

COLUMBIA, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) — W. R. Grace & Co. (NYSE: GRA) today confirmed that it has received a proposal from 40 North Management LLC (“40 North”), one of its shareholders, to acquire all outstanding common shares of the Company for $60 per share in cash, subject to certain conditions.Grace has a portfolio of high-value, specialty businesses and while end markets have been significantly impacted by the pandemic, the fundamentals of its businesses remain strong and demand trends continue to improve. As the Company has communicated, most recently on its third quarter 2020 earnings call, Grace has often pursued opportunities to maximize shareholder value.Consistent with its commitment to all shareholders, Grace’s Board, working with management and its financial advisers, is carefully evaluating and thoroughly...

– Data support continued development of ADP-A2M4CD8 –– On track to start Phase 2 trial in gastroesophageal cancers in the first half of 2021 –PHILADELPHIA, Pa. and OXFORDSHIRE, UK., Nov. 09, 2020 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented data from the dose escalation cohorts of its Phase 1 SURPASS trial using ADP-A2M4CD8 in a poster at the Society for the Immunotherapy of Cancer (“SITC”) Conference.In these cohorts of heavily pre-treated patients with advanced cancers (n=6), three were treated with target doses of 1 billion SPEAR T-cells, and three with target doses of 5 billion. Most adverse events were consistent with those typically experienced by cancer patients undergoing cytotoxic chemotherapy or cancer immunotherapy.“We have...